by Madaline Spencer | Nov 3, 2026
The US Food and Drug Administration (FDA) has granted accelerated approval to Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd), previously referred to as INO-3107, to reduce the frequency of surgery in adults with recurrent respiratory...
by Madaline Spencer | Oct 27, 2026
The US Food and Drug Administration (FDA) has granted accelerated approval to Ultomiris (ravulizumab) for the treatment of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN). IgAN is characterized by the accumulation of IgA antibodies in the...
by Madaline Spencer | Oct 26, 2026
The US Food and Drug Administration (FDA) has approved the oral pellet formulation of once-daily Orladeyo (berotralstat) for prophylactic therapy in patients ages 12 years and older with hereditary angioedema (HAE). HAE is a rare condition characterized by recurrent...
by Madaline Spencer | Oct 23, 2026
The US Food and Drug Administration (FDA) has approved Evoxac (cevimeline HCI) oral solution to address dry mouth in patients with Sjögren’s disease (SjD). SjD is an autoimmune disorder that largely impacts secretory glands. It is also associated with rheumatic...
by Madaline Spencer | Oct 22, 2026
The US Food and Drug Administration (FDA) has approved Enspryng (satralizumab) for the treatment of adults with thyroid eye disease (TED). TED is a chronic endocrine, autoimmune disease characterized by immune-mediated orbital inflammation that greatly...
